Form 8-K - Current report:
SEC Accession No. 0001104659-25-068362
Filing Date
2025-07-16
Accepted
2025-07-16 16:53:39
Documents
13
Period of Report
2025-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2521048d1_8k.htm   iXBRL 8-K 27601
2 EXHIBIT 2.1 tm2521048d1_ex2-1.htm EX-2.1 36486
  Complete submission text file 0001104659-25-068362.txt   237302

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20250715.xsd EX-101.SCH 3026
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20250715_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20250715_pre.xml EX-101.PRE 22366
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2521048d1_8k_htm.xml XML 3685
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
Entero Therapeutics, Inc. (Filer) CIK: 0001604191 (see all company filings)

EIN.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 251127934
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)